Cutera Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Cutera de 33.2% y 2.9% respectivamente, mientras que el BPA crecerá en un 31.9% al año.

Información clave

33.2%

Tasa de crecimiento de los beneficios

31.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.1%
Tasa de crecimiento de los ingresos	2.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	28 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Revenues Working Against Cutera, Inc.'s (NASDAQ:CUTR) Share Price Following 35% Dive

Mar 14

Analysts Are More Bearish On Cutera, Inc. (NASDAQ:CUTR) Than They Used To Be

Aug 11

An Intrinsic Calculation For Cutera, Inc. (NASDAQ:CUTR) Suggests It's 48% Undervalued

Apr 19

Cutera, Inc. (NASDAQ:CUTR) Shares Could Be 49% Below Their Intrinsic Value Estimate

Sep 01

Cutera: The 'AviClear' Sign To Get Bullish

Jun 22

Cutera (NASDAQ:CUTR) Is Carrying A Fair Bit Of Debt

May 27

Returns On Capital Signal Tricky Times Ahead For Cutera (NASDAQ:CUTR)

Apr 22

Cutera: Gains Aren't Surprising After Acne Laser Therapy Cleared

Mar 31

What Does Cutera, Inc.'s (NASDAQ:CUTR) Share Price Indicate?

Feb 23

We Think Cutera (NASDAQ:CUTR) Can Stay On Top Of Its Debt

Jan 08

Revisiting Cutera

Dec 18

We Like These Underlying Return On Capital Trends At Cutera (NASDAQ:CUTR)

Nov 30

Is Cutera (NASDAQ:CUTR) A Risky Investment?

Sep 17

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:CUTR - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	195	-54	N/A	N/A	3
12/31/2025	178	-87	N/A	N/A	5
12/31/2024	163	-131	N/A	N/A	5
12/31/2023	212	-151	-171	-138	N/A
9/30/2023	230	-113	-160	-121	N/A
6/30/2023	247	-81	-146	-105	N/A
3/31/2023	249	-92	-108	-74	N/A
12/31/2022	252	-82	-90	-67	N/A
9/30/2022	251	-78	-62	-47	N/A
6/30/2022	245	-68	-43	-34	N/A
3/31/2022	240	-13	-31	-30	N/A
12/31/2021	231	2	0	1	N/A
9/30/2021	216	8	2	3	N/A
6/30/2021	197	7	5	6	N/A
3/31/2021	165	-12	-5	-4	N/A
12/31/2020	148	-24	-18	-17	N/A
9/30/2020	150	-28	-19	-17	N/A
6/30/2020	157	-29	-17	-16	N/A
3/31/2020	178	-17	-7	-6	N/A
12/31/2019	182	-12	-3	-2	N/A
9/30/2019	175	-37	1	2	N/A
6/30/2019	170	-35	2	3	N/A
3/31/2019	165	-37	1	2	N/A
12/31/2018	163	-31	-1	0	N/A
9/30/2018	165	18	-3	-1	N/A
6/30/2018	162	25	3	4	N/A
3/31/2018	156	29	7	8	N/A
12/31/2017	151	30	13	14	N/A
9/30/2017	142	11	N/A	12	N/A
6/30/2017	134	7	N/A	10	N/A
3/31/2017	125	4	N/A	2	N/A
12/31/2016	118	3	N/A	2	N/A
9/30/2016	110	0	N/A	1	N/A
6/30/2016	103	-2	N/A	-1	N/A
3/31/2016	98	-3	N/A	1	N/A
12/31/2015	95	-4	N/A	-1	N/A
9/30/2015	90	-8	N/A	-5	N/A
6/30/2015	86	-10	N/A	-5	N/A
3/31/2015	81	-11	N/A	-9	N/A
12/31/2014	78	-11	N/A	-4	N/A
9/30/2014	75	-9	N/A	-2	N/A
6/30/2014	73	-8	N/A	-1	N/A
3/31/2014	75	-6	N/A	3	N/A
12/31/2013	75	-5	N/A	4	N/A
9/30/2013	75	-3	N/A	4	N/A
6/30/2013	77	-3	N/A	4	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que CUTR siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que CUTR siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que CUTR siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (2.9% al año) de CUTR crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 2.9% al año) de CUTR crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CUTR se prevé que sea elevada dentro de 3 años.

Cutera Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Cutera, Inc. Provides Revenue Guidance for the Full Year 2024

Consensus EPS estimates fall by 33%

Price target decreased by 59% to US$7.67

Cutera, Inc. Revises Revenue Guidance for the Full Year 2023

Consensus revenue estimates fall by 14%

Price target decreased by 8.9% to US$23.00

Recent updates

Cutera, Inc. to Report Q1, 2024 Results on May 09, 2024

Cutera, Inc. Announces North America Launch of xeo+

Cutera, Inc. Provides Revenue Guidance for the Full Year 2024

Cutera, Inc. announced delayed annual 10-K filing

Revenues Working Against Cutera, Inc.'s (NASDAQ:CUTR) Share Price Following 35% Dive

Consensus EPS estimates fall by 33%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Cutera, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Price target decreased by 59% to US$7.67

High number of new and inexperienced directors

Cutera, Inc. Revises Revenue Guidance for the Full Year 2023

Cutera, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Annual Report on Form 10-Q

Cutera, Inc. announced delayed 10-Q filing

Cutera, Inc. Announces Resignation of Juliane Park from the Board of Directors, Effective as of December 1, 2023

Cutera, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Janet Widmann Resigns from the Board of Directors of Cutera, Inc. Effective November 1, 2023

New minor risk - Market cap size

Cutera, Inc. Appoints Brent Hauser as President, International

Cutera, Inc. Announces the Launch of New Skin Resurfacing and Revitalization Platform Secret DUO

President recently bought US$297k worth of stock

Cutera, Inc. Appoints Jeffrey Jones as Chief Operating Officer, Effective August 28, 2023

Consensus revenue estimates fall by 14%

Analysts Are More Bearish On Cutera, Inc. (NASDAQ:CUTR) Than They Used To Be

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 8.9% to US$23.00

Cutera, Inc. Provides Revenue Guidance for the Full Year 2023

Cutera, Inc. Appoints Talyor C. Harris as President, Effective August 7, 2023

Cutera, Inc. Announces CEO Changes, Effective August 7, 2023

Cutera, Inc. to Report Q2, 2023 Results on Aug 08, 2023

the Gross Law Firm Notifies Shareholders of Cutera, Inc. of A Class Action Lawsuit and A Lead Plaintiff Deadline of July 24, 2023

Cutera, Inc. Announces A New U.S. Food and Drug Administration Clearance of AviClear as A Long-Term Treatment for Mild to Severe Inflammatory Acne Vulgaris

Cutera, Inc. Announces Resignation of J. Daniel Plants as Director

Independent Director notifies of intention to sell stock

Cutera, Inc. Announces Resignation of Joseph E. Whitters from the Board of Directors

Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against Cutera, Inc

Less than half of directors are independent

Cutera, Inc. Announces Board Changes

Cutera, Inc. Appoints Stuart Drummond as Interim Chief Financial Officer

Voce Capital and David Mowry Terminate Proxy Solicitation

Cutera, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings: EPS and revenues miss analyst expectations

An Intrinsic Calculation For Cutera, Inc. (NASDAQ:CUTR) Suggests It's 48% Undervalued

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 57%

Now 21% undervalued after recent price drop

Full year 2022 earnings: EPS misses analyst expectations

Does Cutera (NASDAQ:CUTR) Have A Healthy Balance Sheet?

Price target decreased to US$61.20

Cutera, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Cutera, Inc. Announces AviClear™ Now Broadly Available to US Physicians and Practitioners Upon National Launch

Third quarter 2022 earnings released: US$0.62 loss per share (vs US$0.077 loss in 3Q 2021)

Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022

Cutera, Inc. Announces Committee Appointments

Cutera, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Would Cutera (NASDAQ:CUTR) Be Better Off With Less Debt?

Cutera, Inc. Announces Resignation of Katherine S. Zanotti from the Board

Cutera: Shares Very Attractively Priced, Top-Line Hedged From CMS

Cutera, Inc. (NASDAQ:CUTR) Shares Could Be 49% Below Their Intrinsic Value Estimate

Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cutera, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Cutera, Inc. Announces AviClear Secured Clearance from Health Canada

Cutera: The 'AviClear' Sign To Get Bullish

Cutera (NASDAQ:CUTR) Is Carrying A Fair Bit Of Debt

Cutera, Inc. Reiterates Revenue Guidance for the Full Year of 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus forecasts updated

Cutera, Inc., Annual General Meeting, Jun 15, 2022